Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer

e12024 Background: Triple negative breast cancer in our center represents 21% of all breast cancer cases. In these group of patients, its been suggested that cisplatin could improve breast cancer o...